trial summary · NCT07649304
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
A Feasibility Study of Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma
Trial record from the TrialBase DB dataset, status RECRUITING, condition AIDS-Related Diffuse Large B-cell Lymphoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in treating patients newly-diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific monoclonal antibody, which can bind to two different antigens that are expressed by cancer cells (CD3 and CD20) at the same time. This may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving glofitamab in combination with the R-CHOP regimen may be a safe treatment for patients with …
Source record: https://clinicaltrials.gov/study/NCT07649304
Facts
| registry id | NCT07649304 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | AIDS-Related Diffuse Large B-cell Lymphoma |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 15 |
| start date | 2027-07-05 |
| primary completion | 2028-12-01 |
| completion | 2028-12-01 |
| results posted | not reported |
Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8
- Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8
- Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8
- Plasmablastic Lymphoma
- Primary Effusion Lymphoma
Interventions
- Biopsy Procedure
- Biospecimen Collection
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Computed Tomography
- Cyclophosphamide
- Doxorubicin Hydrochloride
- Echocardiography Test
- Glofitamab
- Positron Emission Tomography
- Prednisone
- Questionnaire Administration
2 more in the dataset.
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, OTHER, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.